EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories

Edwige Kasper iD, Flavie Boulouard, Noémie Basset, Lisa Golmard, Hela Sassi, Emilie Bouvignies, Maud Branchaud, Camille Charbonnier, Nathalie Parodi, Marion Rolain, Juliette Albuisson, Ayman Al Saati iD und 35 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Edwige Kasper und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Univ Rouen Normandie, Normandie Univ, Inserm U1245, and CHU Rouen, Rouen, France. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Hereditary Breast and Ovarian Cancer Syndrome, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 is included in most cancer predisposition multigene panels, especially those exploring Hereditary Breast and Ovarian Cancer (HBOC) predisposition. The purpose of this study was to define the contribution of TP53 pathogenic variants (PV) to the HBOC phenotype by collecting genotypes and phenotypes of 398 patients harboring a TP53 variant identified by 53,085 HBOC panel sequencing in 15 French laboratories. Heterozygous TP53 variants were identified in 0.44% of HBOC panels, evenly distributed between PV and VUS. Breast cancers associated with TP53 were predominantly triple positive, particularly Her2+ breast cancer, in situ cancer, or phyllodes tumors ( p < 0.0001 for both). Interestingly, TP53 PV were identified across all ages in breast cancer patients, with enrichment before 36y. We demonstrated that null variants were linked with the HBOC phenotype, and missense variants, especially with a dominant negative effect, with the LFS phenotype ( p = 0.0096). Patients with breast cancer harboring null variants displayed an earlier age of onset compared to missense ( p = 0.0030). Surprisingly, we identified, in late‐onset cancer patients, TP53 hotspot PV usually identified in classic LFS, which underlines variable penetrance. Thus, this study suggests the existence of two phenotypic entities associated with TP53 PV: clinical LFS and TP53 ‐related breast cancer. The type of TP53 variant, as well as modifying factors reflected in family history, may influence these phenotypes, and both should be considered to define the clinical follow‐up of patients and relatives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Hereditary Breast and Ovarian Cancer SyndromeBreast NeoplasmsHumansFemaleFranceMiddle AgedAdultGenetic Predisposition to DiseaseAgedPhenotype

Stichwörter der Autor:innen

Li–Fraumeni syndromeTP53breast cancergenotype–phenotype correlation

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Department of Genetics, Univ Rouen Normandie, Normandie Univ, Inserm U1245, and CHU Rouen, Rouen, France.
  • Laboratory of Cancer Biology and Genetics, Centre François Baclesse, Caen, France.
  • Inserm U1245, Cancer and Brain Genomics, Normandie Univ, UNICAEN, Rouen, France.
  • Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France.
  • Department of Genetics, Institut Curie, Paris, France.
  • PSL University, Paris, France.

ORCID-Profile: Edwige Kasper, Ayman Al Saati, Nicolas Sevenet, Pierre Vande Perre

Zitieren

APA

Kasper, E., Boulouard, F., Basset, N., Golmard, L., Sassi, H., Bouvignies, E., Branchaud, M., Charbonnier, C., Parodi, N., Rolain, M., Albuisson, J., Al Saati, A., Benusiglio, P., Berthet, P., Bidart, M., Bonnet, C., Bouras, A., Boutry-Kryza, N., Brayotel, F., …, & Houdayer, C. (2025). Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories. International Journal of Cancer. https://doi.org/10.1002/ijc.35475

Vancouver

Kasper E, Boulouard F, Basset N, Golmard L, Sassi H, Bouvignies E, et al. Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories. International Journal of Cancer. 2025. doi:10.1002/ijc.35475

BibTeX
@article{Kasper2025,
  author = {Kasper, Edwige and Boulouard, Flavie and Basset, Noémie and Golmard, Lisa and Sassi, Hela and Bouvignies, Emilie and Branchaud, Maud and Charbonnier, Camille and Parodi, Nathalie and Rolain, Marion and Albuisson, Juliette and Al Saati, Ayman and Benusiglio, Patrick and Berthet, Pascaline and Bidart, Marie and Bonnet, Céline and Bouras, Ahmed and Boutry-Kryza, Nadia and Brayotel, Fanny and Bubien, Virginie and Buisson, Adrien and Castéra, Laurent and Caron, Olivier and Colas, Chrystelle and Coulet, Florence and Delnatte, Capucine and Derangère, Valentin and Fievet, Alice and Garrec, Céline and Gauthier-Villars, Marion and Gay-Bellile, Mathilde and Goussot, Vincent and le Gall, Jessica and Lepage, Mathis and Lokchine, Anna and Perrier, Alexandre and Rouleau, Etienne and Sevenet, Nicolas and Stoppa-Lyonnet, Dominique and Ravel, Jean-Marie and Perre, Pierre Vande and Vaur, Dominique and Vilquin, Paul and Bougeard, Gaëlle and Baert-Desurmont, Stéphanie and Thery, Jean-Christophe and Houdayer, Claude},
  title = {Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35475}
}
Kostenlos starten →